EGFR and neoplasm: These results are counterintuitive but may be explained by one or more of the following events: (a) the EGFR-peptide is presented in association with HLA-A2.1 on the tumor surface in a confirmation unrecognizable by T cells [21], or DC in tumor-bearing individuals might have impaired antigen presenting capability [22].